Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Mini Review Volume 5 Issue 6

MRI-PDFF as a New Paradigm in the Longitudinal Follow-up of Patients with Liver Steatosis

Liliana Sampaio Costa Mendes1* and Wenderson Werneck Xavier Barroso2

1Hepatolology Service, Rede D'or São Luiz, Brasília, Brazil, Institute Hospital de Base do Distrito Federal, Brazil
2Medical School, Centro Universitário de Brasília, Brazil

*Corresponding Author: Liliana Sampaio Costa Mendes, Hepatolology Service, Rede D'or São Luiz, Brasília, Brazil, Institute Hospital de Base do Distrito Federal, Brazil.

Received: May 03, 2022; Published: May 20, 2022



Background: Hepatic steatosis linked to metabolic syndrome (MS) can lead to liver fibrosis, decompensation of liver cirrhosis and hepatocarcinoma (HCC). However, the focus of attention is usually on accessing hepatic fibrosis rather than accessing inflammation, when it would be more possible to intervene and minimize consequences.

Objective: Put into perspectives the current new concepts in liver steatosis and diagnose image methods for steatosis with liver Ultrasound (US), computerized tomography (CT), Magnetic Resonance Imaging (MRI), Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and other noninvasive marks of liver fibrosis and steatosis and the relationship of improvement in liver steatosis inflammation.

Design: Review of recent medical literature about the new concepts in Metabolic Association Fatty Liver Disease (MAFLD), new non-invasive diagnostic features for Non-Alcoholic Fatty Liver Disease (NAFLD) and the impact of nonalcoholic steatohepatitis (NASH) trials in access the improvement in liver steatosis and the correlation with improvement in histologic liver inflammation.

Salient Features: There is a correlation between improvement in liver steatosis accessed by MRI-PDFF and improvement in liver histologic NASH. 

Conclusions: MRI-PDFF has established itself as a reliable standard for longitudinally assessing hepatic steatosis, as it is accurate, non-invasive and because variation in fat percentage correlates with NASH resolution and hepatocyte ballooning, being a new paradigm to predict response in NASH trials. Furthermore, a focus on resolving inflammation is likely to be associated with better outcomes in NAFLD and MAFLD.

Keywords: Non-alcoholic Fatty Liver Disease (NAFLD); Metabolic Associated Fatty Liver Disease (MAFLD); Non-alcoholic Steatohepatitis (NASH); Non-invasive Diagnostic Methods; Magnetic Resonance Imaging (MRI); Proton Density Fat Fraction (PDFF).



  1. Younossi Zobair M., et al. “Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes”. Hepatology1 (2016): 73-84.
  2. Younossi Zobair M., et al. “The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis”. Journal of Hepatology4 (2019): 793-801.
  3. International Diabetes Federation. IDF DIABETES ATLAS Seventh Edition (2015).
  4. “EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease”. Journal of Hepatology6 (2016): 1388-402.
  5. Singh, Siddharth., et al. “Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies”. Clinical Gastroenterology and Hepatology4 (2015): 643.e1-654.e9.
  6. Torres Dawn M., et al. “Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease”. Clinical Gastroenterology and Hepatology 8 (2012): 837-858.
  7. Eslam Mohammed., et al. “A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement”. Journal of Hepatology1 (2020): 202-209.
  8. Lee Yong., et al. “Sarcopenia Is Associated with Significant Liver Fibrosis Independently of Obesity and Insulin Resistance in Nonalcoholic Fatty Liver Disease: Nationwide Surveys (KNHANES 2008-2011)”. Hepatology3 (2016): 776-786.
  9. Hsu Cynthia., et al. “Magnetic Resonance vs Transient Elastography Analysis of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants”. Clinical Gastroenterology and Hepatology4 (2019): 630.e1-637.e8.
  10. Tsai Eugenia and Tai-Ping Lee. “Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography”. Clinics in Liver Disease1 (2018): 73-92.
  11. Feldstein Ariel E., et al. “Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis: A Multicenter Validation Study”. Hepatology4 (2009): 1072-1078.
  12. Bedossa Pierre. “Utility and Appropriateness of the Fatty Liver Inhibition of Progression (FLIP) Algorithm and Steatosis, Activity, and Fibrosis (SAF) Score in the Evaluation of Biopsies of Nonalcoholic Fatty Liver Disease”. Hepatology2 (2014): 565-575.
  13. Brunt Elizabeth M., et al. “Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings”. Hepatology3 (2011): 810-820.
  14. Ekstedt Mattias., et al. “Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD after up to 33 Years of Follow-Up”. Hepatology5 (2015): 1547-1554.
  15. Kleiner David E., et al. “Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease”. Hepatology6 (2005): 1313-1321.
  16. Caussy Cyrielle, et al. “Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials”. Hepatology2 (2018): 763-772.
  17. Loomba Rohit., et al. “Multicenter Validation of Association between Decline in MRI-PDFF and Histologic Response in NASH”. Hepatology4 (2020): 1219-1229.
  18. Harrison Stephen A., et al. “Resmetirom (MGL-3196) for the Treatment of Non-Alcoholic Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial”. The Lancet10213 (2019): 2012-2024.
  19. Sugimoto Katsutoshi., et al. “The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis”. Radiology3 (2020): 532-540.
  20. Eddowes Peter J., et al. “Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease”. Gastroenterology6 (2019): 1717-1730.


Citation: Liliana Sampaio Costa Mendes and Wenderson Werneck Xavier Barroso. “MRI-PDFF as a New Paradigm in the Longitudinal Follow-up of Patients with Liver Steatosis". Acta Scientific Gastrointestinal Disorders 5.6 (2022): 38-42.


Acceptance rate35%
Acceptance to publication20-30 days

Indexed In

News and Events

Contact US